Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost of illness and economic burden of chronic lymphocytic leukemia

1 Jan 2013

Abstract excerpt

BACKGROUND: Chronic lymphocytic leukemia (CLL) is a slowly progressing but fatal disease that imposes a high economic burden on sickness funds and society. The objective of this study was to analyze and compare the direct and indirect costs of CLL in Germany from the perspective of the sickness funds and society and analyze the burden of the disease. METHODS: Using a database of 7.6 million enrolled individuals,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 23425552
DOI: 10.1186/1750-1172-8-32

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost of illness and economic burden of chronic lymphocytic leukemiaPMID 23425552Read ↗

Impact of Oral Targeted Therapy on the Economic Burden of Chronic Lymphocytic Leukemia in Canada.Semantic proximity Read ↗

Follicular lymphoma or diffuse large B-cell lymphoma: a population based analysis of epidemiological and health economic aspects in GermanySemantic proximity Read ↗

Cost-effectiveness of anti-CD20 monoclonal antibody associated with fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia in the Brazilian public health system (SUS)Semantic proximity Read ↗

Cost-effectiveness Analysis of Rituximab Associated With Fludarabine and Cyclophosphamide (R-FC) for the First-line Treatment of Chronic Lymphocytic Leukemia Under the Brazilian Public Health System (SUS).Semantic proximity Read ↗

Optimal Management of Chronic Lymphocytic Leukemia and Economic Constraints.Semantic proximity Read ↗

Who Bears the Highest Costs of Breast Cancer? A Cost-of-Illness Study in Poland from a Societal PerspectiveSemantic proximity Read ↗

First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study.Semantic proximity Read ↗

Clinical and economic burden of first-line chemoimmunotherapy by risk status in chronic lymphocytic leukemia.Semantic proximity Read ↗

Established and suggested exposures on CLL/SLL etiology: Results from the CLL-MCC-Spain study.Semantic proximity Read ↗

An International Study of Caregiver-Reported Burden and Quality of Life in Metachromatic LeukodystrophySemantic proximity Read ↗

The Economic Burden of Illness in Pediatric Acute Lymphoblastic Leukemia (ALL) Patients from a Commercial and Medicaid Insurance PerspectiveSemantic proximity Read ↗

Ibrutinib versus bendamustine plus rituximab for first-line treatment of older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: A lifetime economic research studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.